posted on 2013-01-18, 00:00authored byXia Hong, Mark Z. Ma, Jeffrey C. Gildersleeve, Sudipa Chowdhury, Joseph J. Barchi, Roy A. Mariuzza, Michael B. Murphy, Li Mao, Zeev Pancer
Glycan-binding proteins are important for a wide variety
of basic
research and clinical applications, but proteins with high affinity
and selectivity for carbohydrates are difficult to obtain. Here we
describe a facile and cost-effective strategy to generate monoclonal
lamprey antibodies, called lambodies, that target glycan determinants.
We screened a library of yeast surface-displayed (YSD) lamprey variable
lymphocyte receptors (VLR) for clones that can selectively bind various
biomedically important glycotopes. These glycoconjugates included
tumor-associated carbohydrate antigens (Tn and TFα), Lewis antigens
(LeA and LeX), N-glycolylneuraminic acid, targets
of broadly neutralizing HIV antibodies (poly-Man9 and the HIV gp120),
and the glycoproteins asialo-ovine submaxillary mucin (aOSM) and asialo-human
glycophorin A (aGPA). We isolated clones that bind each of these targets
in a glycan-dependent manner and with very strong binding constants,
for example, 6.2 nM for Man9 and 44.7 nM for gp120, determined by
surface plasmon resonance (SPR). One particular lambody, VLRB.aGPA.23,
was shown by glycan array analysis to be selective for the blood group
H type 3 trisaccharide (BG-H3, Fucα1-2Galβ1-3GalNAcα),
aGPA, and TFα (Galβ1-3GalNAcα), with affinity constants
of 0.2, 1, and 8 nM, respectively. In human tissue microarrays this
lambody selectively detected cancer-associated carbohydrate antigens
in 14 different types of cancers. It stained 27% of non-small cell
lung cancer (NSCLC) samples in a pattern that correlated with poor
patient survival. Lambodies with exquisite affinity and selectivity
for glycans may find myriad uses in glycobiology and biomedical research.